Copyright medicaldialogues
Mankind Pharma Ltd has posted a 21 percent year-on-year decline in its consolidated profit after tax (PAT) to Rs 520 crore for the quarter ended September 30, 2025. The drug major had posted a PAT of Rs 661 crore in the same quarter last year. Despite the profit dip, the company’s revenue from operations rose to Rs 3,697 crore during the July–September period.“Mankind’s revenue increased by 20.8% supported by outperformance in Chronic and BSV consolidation, partially impacted by GST disruption. While chronic continued an outperformance led by 1.3x and 1.2x in Cardiac and Anti- diabetes respectively, OTC was impacted due to heavy rains along with GST 2.0 and we expect growth recovery in H2," Rajeev Juneja, Vice Chairman & Managing Director of the company stated."BSV growth initiatives progressing well - with double digit sequential growth led by mandate brands We remain confident of delivering sustainable long-term growth led by four key pillars - steady base business, fast growing specialty chronic, high potential OTC business, and super specialty BSV portfolio," he added.Mankind Pharma is a pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. The company's domestic pharmaceuticals business is present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynaecology, VMN and respiratory. In the consumer healthcare business, the company operates in the pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of BSV, Mankind Pharma has further strengthened its leadership in the domestic women’s health segment. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products.Read also: Mankind Pharma MD Rajeev Juneja takes over as PHDCCI President
